Results 231 to 240 of about 3,189,219 (271)
Some of the next articles are maybe not open access.
Iron Toxicity and Chelation Therapy
International Journal of Hematology, 2002Iron is an essential mineral for normal cellular physiology, but an excess can result in cell injury. Iron in low-molecular-weight forms may play a catalytic role in the initiation of free radical reactions. The resulting oxyradicals have the potential to damage cellular lipids, nucleic acids, proteins, and carbohydrates; the result is wide-ranging ...
Robert S, Britton +2 more
openaire +2 more sources
Iron-chelation therapy: an update
The Hematology Journal, 2004Chronically transfused patients develop iron overload that leads to organ damage and ultimately to death. The introduction of the iron-chelating agent, desferrioxamine mesylate, dramatically improved the life expectancy of these patients. However, the very demanding nature of this treatment (subcutaneous continuous infusion via a battery-operated ...
Massimo, Franchini, Dino, Veneri
openaire +2 more sources
Current Opinion in Hematology, 1995
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
Iron Chelation Therapy for Malaria
1994Malaria is one of the most devastating and geographically widespread infections in man. Of the four protozoan species that cause malaria in humans, Plasmodium falciparum is responsible for the most severe clinical consequences including coma, profound anemia, renal failure and death. It is estimated that in 1986 there were 234 million clinical cases of
V R, Gordeuk +2 more
openaire +2 more sources
Reviews in Clinical and Experimental Hematology, 2000
In chronic anemias associated with iron overload, iron chelation therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for the treatment of transfusional iron overload since the early 1960s, the era of modern and effective iron chelation ...
Chaim Hershko, A. Victor Hoffbrand
openaire +1 more source
In chronic anemias associated with iron overload, iron chelation therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for the treatment of transfusional iron overload since the early 1960s, the era of modern and effective iron chelation ...
Chaim Hershko, A. Victor Hoffbrand
openaire +1 more source
Seminars in Hematology, 2001
Iron chelators are used in clinical practice to protect patients from the complications of iron overload and iron toxicity because there is no physiologic way for excess iron to be actively excreted. Deferoxamine, the only iron-chelating agent available for clinical use in the United States, is administered as a prolonged (8 to 24 hours) infusion ...
openaire +2 more sources
Iron chelators are used in clinical practice to protect patients from the complications of iron overload and iron toxicity because there is no physiologic way for excess iron to be actively excreted. Deferoxamine, the only iron-chelating agent available for clinical use in the United States, is administered as a prolonged (8 to 24 hours) infusion ...
openaire +2 more sources
Chelation therapy in acute iron poisoning
The Journal of Pediatrics, 1967Deferoxamine, a highly specific iron chelating agent, was used in association with supportive therapy in 14 children with acute iron intoxication of mild to moderate severity. The serum iron levels and iron excretion of these patients were compared with those of 8 patients who received only supportive therapy. A rapid drop in serum iron levels occurred
S, Leikin, P, Vossough, F, Mochir-Fatemi
openaire +2 more sources
Chelation therapy for iron overload
Current Gastroenterology Reports, 2007Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints. Because physiologic mechanisms to excrete iron are very limited, patients with iron overload and its complications need safe, effective therapy that is compatible with their coexisting medical ...
openaire +2 more sources
The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry, 2003This review focuses on advances and strategies in the use of iron chelators as anti-tumor therapies. Although the development of iron chelators for human disease has focused primarily on their use in the treatment of secondary iron overload, chelators may also be useful anti-tumor agents. They can deplete iron or cause oxidative stress in the tumor due
Joan L, Buss +2 more
openaire +2 more sources
Recent Developments in Iron Chelation Therapy
Klinische Pädiatrie, 2007Since 1962, desferrioxamine (deferoxamine, DFO) has been utilized for the treatment of secondary hemosiderosis. For about 30 years, DFO therapy has been performed as nightly continuous subcutaneous infusion. About 20 years ago, the first oral iron chelator (deferiprone, DFP) was presented.
H, Cario +5 more
openaire +2 more sources